[{"id":"7b0b3ce3-25fe-4440-95cb-b47e010ed12d","acronym":"UNIVERSE","url":"https://clinicaltrials.gov/study/NCT06640530","created_at":"2025-02-26T07:20:06.640Z","updated_at":"2025-02-26T07:20:06.640Z","phase":"Phase 3","brief_title":"Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® As Monotherapy in Subjects with Advanced Melanoma of the Skin","source_id_and_acronym":"NCT06640530 - UNIVERSE","lead_sponsor":"Biocad","biomarkers":" TNFRSF10C","pipe":"","alterations":" ","tags":["TNFRSF10C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 392","initiation":"Initiation: 03/21/2024","start_date":" 03/21/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-10-14"},{"id":"5b9f269d-cb26-4760-9957-1726b97133c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06112808","created_at":"2023-11-02T15:12:34.420Z","updated_at":"2024-07-02T16:35:30.513Z","phase":"Phase 1","brief_title":"A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin","source_id_and_acronym":"NCT06112808","lead_sponsor":"Biocad","biomarkers":" CD4 • TNFRSF10C","pipe":"","alterations":" ","tags":["CD4 • TNFRSF10C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 05/29/2023","start_date":" 05/29/2023","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-11-03"}]